In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.

AUTOR(ES)

Miyazaki, S

RESUMO

We compared the in vivo and in vitro activities of CS-940, a new fluoroquinolone, with those of a group of other drugs. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.

Documentos Relacionados

• In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
• In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
• In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
• Antimicrobial activity of CS-940, a new trifluorinated quinolone.
• In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens